[{"id":"4bf912ed-2f96-4d90-aef7-e45022410420","acronym":"","url":"https://clinicaltrials.gov/study/NCT00186888","created_at":"2025-07-19T13:43:51.175Z","updated_at":"2025-07-19T13:43:51.175Z","phase":"Phase 3","brief_title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","source_id_and_acronym":"NCT00186888","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" ABCG2 • CYP3A4","pipe":"","alterations":" ","tags":["ABCG2 • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 04/07/2005","start_date":" 04/07/2005","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 11/12/2024","study_completion_date":" 11/12/2024","last_update_posted":"2025-04-15"},{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"81796e46-09bd-4096-9e4d-f21de4f6ddd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01247597","created_at":"2021-01-18T05:01:29.106Z","updated_at":"2025-02-25T13:38:59.492Z","phase":"","brief_title":"DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study","source_id_and_acronym":"NCT01247597","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" DICER1","pipe":"","alterations":" ","tags":["DICER1"],"overall_status":"Recruiting","enrollment":" Enrollment 1500","initiation":"Initiation: 02/13/2011","start_date":" 02/13/2011","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"35c5e79b-54b0-43e1-b61a-1b50d58d242e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06725173","created_at":"2025-02-25T14:43:58.802Z","updated_at":"2025-02-25T14:43:58.802Z","phase":"","brief_title":"Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.","source_id_and_acronym":"NCT06725173","lead_sponsor":"University of Washington","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2025-02-14"},{"id":"39be432b-e1d2-4ded-8099-18c4960548fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06805825","created_at":"2025-02-25T15:15:39.171Z","updated_at":"2025-02-25T15:15:39.171Z","phase":"Phase 1","brief_title":"A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit","source_id_and_acronym":"NCT06805825","lead_sponsor":"Novelty Nobility, Inc.","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NN3201"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 02/03/2025","start_date":" 02/03/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-13"},{"id":"c388e765-68a9-4c36-8000-4ede187305c8","acronym":"CA224-094","url":"https://clinicaltrials.gov/study/NCT04552223","created_at":"2021-01-18T21:45:58.107Z","updated_at":"2025-02-25T14:29:34.845Z","phase":"Phase 2","brief_title":"Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma","source_id_and_acronym":"NCT04552223 - CA224-094","lead_sponsor":"Jose Lutzky, MD","biomarkers":" LAG3 • CTLA4","pipe":"","alterations":" ","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2025-02-13"},{"id":"8faa9c2f-7698-40c3-8644-3401597d3da2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05628883","created_at":"2022-11-29T15:57:45.457Z","updated_at":"2025-02-25T16:33:12.261Z","phase":"Phase 1","brief_title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","source_id_and_acronym":"NCT05628883","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF • IL2","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TIDAL-01"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/22/2022","start_date":" 11/22/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-07"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"c40fa03c-9c20-4928-9562-c4d2f144ca96","acronym":"DAR-UM-2","url":"https://clinicaltrials.gov/study/NCT05987332","created_at":"2023-08-14T15:10:06.767Z","updated_at":"2025-02-25T16:27:34.251Z","phase":"Phase 2/3","brief_title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","source_id_and_acronym":"NCT05987332 - DAR-UM-2","lead_sponsor":"IDEAYA Biosciences","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Xalkori (crizotinib) • Yervoy (ipilimumab) • dacarbazine • darovasertib (IDE196)"],"overall_status":"Recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 01/15/2028","study_completion_date":" 01/15/2028","last_update_posted":"2025-02-04"},{"id":"96a46201-6c05-499a-b5e8-480c4ba52158","acronym":"","url":"https://clinicaltrials.gov/study/NCT03382158","created_at":"2021-01-18T16:41:19.886Z","updated_at":"2025-02-25T17:29:36.962Z","phase":"","brief_title":"International PPB/DICER1 Registry","source_id_and_acronym":"NCT03382158","lead_sponsor":"Children's Hospitals and Clinics of Minnesota","biomarkers":" DICER1","pipe":"","alterations":" ","tags":["DICER1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 3400","initiation":"Initiation: 12/06/2016","start_date":" 12/06/2016","primary_txt":" Primary completion: 12/06/2030","primary_completion_date":" 12/06/2030","study_txt":" Completion: 12/06/2035","study_completion_date":" 12/06/2035","last_update_posted":"2025-01-30"},{"id":"65eed3dd-6e61-408e-98c2-7b567021d3e7","acronym":"KEYNOTE-G05","url":"https://clinicaltrials.gov/study/NCT06784648","created_at":"2025-02-25T16:11:37.790Z","updated_at":"2025-02-25T16:11:37.790Z","phase":"Phase 1/2","brief_title":"Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT06784648 - KEYNOTE-G05","lead_sponsor":"BioInvent International AB","biomarkers":" PD-1 • FCGR2A","pipe":"","alterations":" ","tags":["PD-1 • FCGR2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • BI-1607"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 12/11/2024","start_date":" 12/11/2024","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2025-01-20"},{"id":"49dce72b-9d7c-4760-9f04-db0fc8e432e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06070012","created_at":"2023-10-06T14:11:25.919Z","updated_at":"2025-02-25T16:27:38.972Z","phase":"Phase 2","brief_title":"Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma","source_id_and_acronym":"NCT06070012","lead_sponsor":"Diwakar Davar","biomarkers":" LAG3 • CTLA4","pipe":" | ","alterations":" HLA-A*02:01","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kimmtrak (tebentafusp-tebn)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 01/31/2025","start_date":" 01/31/2025","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2029","study_completion_date":" 11/30/2029","last_update_posted":"2025-01-06"},{"id":"e5c65e48-a957-4b92-b313-8ca9fc5212ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03435952","created_at":"2021-01-18T16:57:22.872Z","updated_at":"2025-02-25T16:07:34.095Z","phase":"Phase 1","brief_title":"Pembrolizumab with Intratumoral Injection of Clostridium Novyi-NT","source_id_and_acronym":"NCT03435952","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Clostridium novyi-NT"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-10-31"},{"id":"9795b4cb-6f73-4ce5-a9a8-6ba8acc8d386","acronym":"Keynote MK-3475-B66","url":"https://clinicaltrials.gov/study/NCT03611868","created_at":"2021-01-18T17:45:12.835Z","updated_at":"2025-02-25T16:08:10.551Z","phase":"Phase 1/2","brief_title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","source_id_and_acronym":"NCT03611868 - Keynote MK-3475-B66","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" ATM mutation • TP53 wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/29/2018","start_date":" 08/29/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2024-07-19"},{"id":"2d78abd7-6d51-41e8-9d45-561b60e6b952","acronym":"HAMMER I","url":"https://clinicaltrials.gov/study/NCT05169957","created_at":"2021-12-27T15:54:22.593Z","updated_at":"2024-07-02T16:34:59.720Z","phase":"Phase 1","brief_title":"Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)","source_id_and_acronym":"NCT05169957 - HAMMER I","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 06/13/2023","primary_completion_date":" 06/13/2023","study_txt":" Completion: 06/13/2025","study_completion_date":" 06/13/2025","last_update_posted":"2024-05-31"},{"id":"69c0c3d7-d12e-4846-a87b-98d5f38f2dcd","acronym":"SJDAWN","url":"https://clinicaltrials.gov/study/NCT03434262","created_at":"2021-01-18T16:56:26.116Z","updated_at":"2025-02-25T15:54:00.489Z","phase":"Phase 1","brief_title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","source_id_and_acronym":"NCT03434262 - SJDAWN","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 05/24/2024","study_completion_date":" 05/24/2024","last_update_posted":"2024-05-31"},{"id":"f270357c-b837-458a-950f-910b0ee31575","acronym":"","url":"https://clinicaltrials.gov/study/NCT01587352","created_at":"2023-11-26T19:51:41.019Z","updated_at":"2024-07-02T16:35:00.381Z","phase":"Phase 2","brief_title":"Vorinostat in Treating Patients With Metastatic Melanoma of the Eye","source_id_and_acronym":"NCT01587352","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GNAQ • BAP1 • GNA11","pipe":"","alterations":" ","tags":["GNAQ • BAP1 • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/29/2012","start_date":" 05/29/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-29"},{"id":"a4243371-e966-46ad-813b-48b6cc83f0e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02858869","created_at":"2021-01-18T14:01:58.994Z","updated_at":"2025-02-25T16:05:04.203Z","phase":"Phase 1","brief_title":"Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases","source_id_and_acronym":"NCT02858869","lead_sponsor":"Emory University","biomarkers":" PD-L1 • BRAF • ALK","pipe":"","alterations":" ","tags":["PD-L1 • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 10/04/2016","start_date":" 10/04/2016","primary_txt":" Primary completion: 11/19/2020","primary_completion_date":" 11/19/2020","study_txt":" Completion: 10/28/2023","study_completion_date":" 10/28/2023","last_update_posted":"2024-05-13"},{"id":"a532ecf0-a3c8-400f-b42b-9187fc8e7481","acronym":"RIVERBOAT","url":"https://clinicaltrials.gov/study/NCT03932786","created_at":"2021-01-18T19:22:16.373Z","updated_at":"2024-07-02T16:35:04.323Z","phase":"","brief_title":"Studying Health Outcomes After Treatment in Patients With Retinoblastoma","source_id_and_acronym":"NCT03932786 - RIVERBOAT","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"],"overall_status":"Recruiting","enrollment":" Enrollment 900","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2024-05-10"},{"id":"447deee0-48df-4d5d-a0f4-8e3810a39c90","acronym":"DepiSCARRH","url":"https://clinicaltrials.gov/study/NCT03026998","created_at":"2021-01-18T14:53:55.583Z","updated_at":"2024-07-02T16:35:06.766Z","phase":"","brief_title":"MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma (DepiSCARRH)","source_id_and_acronym":"NCT03026998 - DepiSCARRH","lead_sponsor":"Institut Curie","biomarkers":" RB1","pipe":" | ","alterations":" RB1 deletion • RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 03/19/2017","start_date":" 03/19/2017","primary_txt":" Primary completion: 03/01/2034","primary_completion_date":" 03/01/2034","study_txt":" Completion: 03/01/2034","study_completion_date":" 03/01/2034","last_update_posted":"2024-04-30"},{"id":"711124ce-0659-42bd-8b65-60940e5975b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05415072","created_at":"2022-06-10T12:58:54.272Z","updated_at":"2024-07-02T16:35:07.121Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","source_id_and_acronym":"NCT05415072","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" GNAQ","pipe":"","alterations":" ","tags":["GNAQ"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DYP688"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-04-29"},{"id":"84a8bbc2-ef05-45fb-8d2a-c2429e123035","acronym":"STRIvE-02","url":"https://clinicaltrials.gov/study/NCT04483778","created_at":"2021-01-18T21:31:43.742Z","updated_at":"2024-07-02T16:35:07.947Z","phase":"Phase 1","brief_title":"B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT04483778 - STRIvE-02","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression • CD19 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2024-04-23"},{"id":"d4abf529-67b2-46e8-a739-11f0991f275a","acronym":"RTB","url":"https://clinicaltrials.gov/study/NCT03284268","created_at":"2021-01-18T16:13:30.310Z","updated_at":"2024-07-02T16:35:08.341Z","phase":"","brief_title":"Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma","source_id_and_acronym":"NCT03284268 - RTB","lead_sponsor":"Fundació Sant Joan de Déu","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zabilugene almadenorepvec (VCN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-22"},{"id":"38d6c31c-a42e-4154-b3f7-edcf460d915e","acronym":"NCI-2018-01211","url":"https://clinicaltrials.gov/study/NCT03025256","created_at":"2021-01-18T14:53:25.115Z","updated_at":"2024-07-02T16:35:10.137Z","phase":"Phase 1","brief_title":"Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease","source_id_and_acronym":"NCT03025256 - NCI-2018-01211","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • IL2","pipe":"","alterations":" ","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/02/2018","start_date":" 05/02/2018","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-04-11"}]